| Domain | Best-supported finding | Evidence strength/type | Suggested ontology terms |
|---|---|---|---|
| Disease identity | **Midface hypoplasia, hearing impairment, elliptocytosis, and nephrocalcinosis (MFHEIN; OMIM 300990)** is an ultra-rare, multisystem AMMECR1-related disorder distinct from the broader COL4A5-containing AMME contiguous-gene deletion syndrome. | Strong disease-level evidence from multiple human case series; boundaries remain evolving because very few patients are known. (pqac-00000000, pqac-00000012, pqac-00000020) | MONDO: AMMECR1-related MFHEIN; HP: phenotypic abnormality |
| Cause and inheritance | Hemizygous missense or loss-of-function variants and intragenic/whole-gene deletions affecting **AMMECR1** cause an X-linked disorder. Affected males usually have the fuller phenotype; heterozygous females can manifest features depending partly on X-inactivation. | Strong human genetic segregation plus functional evidence; variable expressivity demonstrated. (pqac-00000009, pqac-00000010, pqac-00000017) | X-linked inheritance (HP:0010985); AMMECR1; germline variant |
| Core phenotypes | Recurrent findings include midface hypoplasia, short stature or growth failure, developmental/speech delay, sensorineural hearing loss, and subtle or overt elliptocytosis. | Moderate evidence from small human series; no reliable population-level frequencies. Elliptocytosis is variably penetrant and can be absent on an early smear. (pqac-00000002, pqac-00000013, pqac-00000020) | Midface hypoplasia (HP:0011800); short stature (HP:0004322); global developmental delay (HP:0001263); speech delay (HP:0000750); sensorineural hearing impairment (HP:0000407); elliptocytosis (HP:0004445) |
| Associated phenotypes | Nephrocalcinosis/hypercalciuria, hypotonia, cleft or submucous cleft palate with bifid uvula, skeletal abnormalities, congenital hip dysplasia, joint hypermobility, cardiac defects, genital anomalies, talipes, ocular findings, and fetal edema have been reported. Some may be uncommon, incidental, or attributable to neighboring genes in larger deletions. | Limited human case evidence; causality is strongest for growth, skeletal, cardiac, palate, and hearing phenotypes but less secure for nephrocalcinosis and some ocular findings. (pqac-00000002, pqac-00000021, pqac-00000023) | Nephrocalcinosis (HP:0000121); hypercalciuria (HP:0002150); muscular hypotonia (HP:0001252); cleft palate (HP:0000175); bifid uvula (HP:0000193); joint hypermobility (HP:0001382); talipes equinovarus (HP:0001762) |
| Temporal course | Congenital findings may be detectable prenatally or neonatally; hypotonia, feeding problems, skeletal/palatal anomalies, and dysmorphism occur early. Hearing loss and elliptocytosis may emerge or worsen during childhood, while speech development and facial appearance can improve with age and intervention. | Longitudinal observations from individual patients, not a formal natural-history cohort. (pqac-00000001, pqac-00000005, pqac-00000006, pqac-00000018) | Congenital onset (HP:0003577); infantile onset (HP:0003593); childhood onset (HP:0011463); progressive hearing impairment (HP:0001730) |
| Female carriers | Three related heterozygous females with an exon-4 deletion all reported mild-to-moderate SNHL; one also had soft-palate cleft and congenital hip dysplasia. Peripheral-blood X-inactivation ranged from 60:40 to 90:10, suggesting—but not proving—a severity relationship. | Direct human pedigree, audiometric, deletion, and X-inactivation evidence; penetrance cannot be generalized from one family. (pqac-00000008, pqac-00000010, pqac-00000014) | Female limited expression; skewed X-inactivation; sensorineural hearing impairment (HP:0000407); cleft soft palate (HP:0000185); congenital hip dislocation/dysplasia |
| Diagnostics | Phenotype-led evaluation should include sequencing and deletion/duplication analysis of AMMECR1, peripheral blood smear, audiology, renal ultrasound plus renal function/calcium studies, developmental and palatal assessment, growth/skeletal examination, and consideration of cardiac and ophthalmic assessment. WES identified the original missense family; CMA detects regional deletions; WGS may help when sequencing and copy-number tests are unrevealing. | WES, Sanger segregation, blood-smear, audiometric, ultrasound, and microarray approaches are documented in cases; no consensus diagnostic criteria or validated biomarker exists. (pqac-00000016, pqac-00000017, pqac-00000021, pqac-00000022) | Genetic testing; peripheral blood smear; pure-tone audiometry; renal ultrasonography; developmental assessment |
| Key differential | Exclude Xq22.3–q23 contiguous deletions involving **COL4A5**, which add Alport nephropathy/hematuria and related ocular manifestations. Other hearing-loss-plus-nephrocalcinosis disorders and hereditary red-cell membrane disorders should be considered according to biochemical findings. | Direct genotype–phenotype comparison supports the COL4A5 distinction; broader differential is clinical inference. (pqac-00000016, pqac-00000018, pqac-00000019) | Alport syndrome; hematuria (HP:0000790); distal renal tubular acidosis; hereditary elliptocytosis |
| Management | No disease-modifying therapy is established. Reported real-world care includes hearing aids, cleft-palate repair, developmental/speech support, surveillance of renal, growth, skeletal, and cardiac abnormalities, and individualized treatment of complications. Growth-hormone response was reported in one short-stature patient but is not validated as syndrome-specific therapy. | Case-level treatment evidence only; no controlled treatment studies. Hearing and palate treatment was followed by improved speech/language in affected children. (pqac-00000002, pqac-00000010, pqac-00000015) | Hearing aid; palatoplasty; speech therapy; developmental intervention; genetic counseling; growth-hormone therapy |
| Cellular mechanism | AMMECR1 is a nuclear protein containing two RAGNYA folds. The p.Gly177Asp protein showed abnormal, nonuniform nuclear localization and fewer transfected GFP-positive cells, consistent with protein dysfunction or instability. AMMECR1 loss was associated with increased AMMECR1L expression, possibly providing partial compensation. | Nuclear localization and mutant mislocalization demonstrated in cultured cells; instability and AMMECR1L compensation remain inferred rather than proven. (pqac-00000003, pqac-00000022, pqac-00000024) | GO: nucleus (GO:0005634); protein localization to nucleus; protein stability; nucleic-acid binding; CL: cultured human epithelial cell |
| Molecular pathway | RAGNYA-fold structure predicts nucleic-acid interaction and possibly an RNA-associated catalytic role; coexpression with cell-cycle genes suggests a developmental growth mechanism. No specific Wnt, MAPK, mTOR, PI3K–AKT, immune, metabolic, or epigenetic pathway has been causally demonstrated. | Structural/computational prediction and coexpression evidence; biochemical substrate and downstream pathway remain unknown. (pqac-00000009, pqac-00000024, pqac-00000025) | GO: nucleic acid binding; cell-cycle regulation; developmental growth; RNA modification—provisional only |
| Affected tissues/cells | Clinical evidence implicates craniofacial mesenchyme/palate, inner ear, erythrocytes, growth plate/bone, kidney, heart, and nervous/developmental systems. AMMECR1 protein expression was demonstrated in developing human fetal cochlear epithelium at gestational weeks 13 and 17. | Multisystem human phenotype plus direct fetal-inner-ear immunohistochemistry; disease-critical cell populations are otherwise undefined. (pqac-00000008, pqac-00000010, pqac-00000021) | CL: erythrocyte (CL:0000232); epithelial cell (CL:0000066); chondrocyte (CL:0000138); UBERON: inner ear, kidney, midface, palate, bone, heart |
| Model organisms | Zebrafish ammecr1 knockdown altered approximately 90% of transcripts and generated patient-reminiscent developmental phenotypes. Mouse and human proteins share approximately 95.2% amino-acid identity, supporting evolutionary conservation, but no disease-specific mammalian knockout phenotype is established in the cited evidence. | Functional zebrafish knockdown plus comparative mouse-ortholog evidence; morpholino limitations apply and complete human MFHEIN recapitulation is unproven. (pqac-00000009, pqac-00000024, pqac-00000025) | Danio rerio (NCBITaxon:7955); Mus musculus (NCBITaxon:10090); gene knockdown; developmental abnormality |
| Epidemiology and evidence gaps | Prevalence, incidence, carrier frequency, sex ratio, survival, quality-of-life scores, penetrance, and prognostic biomarkers are unknown. Published evidence consists of a handful of families and deletion cases, precluding meaningful percentages. | Very low-certainty epidemiology; absence of registries and natural-history cohorts. (pqac-00000000, pqac-00000009, pqac-00000010) | Rare disease; ultra-rare genetic disease; natural-history study needed |
| Trials and advanced therapies | No AMMECR1/MFHEIN-specific interventional trial, gene therapy, RNA therapy, cell therapy, targeted drug, or validated pharmacogenomic strategy was identified. | Clinical-trial search negative; current care is supportive and complication-directed. | Supportive care; symptom management; no applicable investigational intervention term |


*Table: Concise knowledge-base summary separating well-supported human and functional findings from hypotheses and evidence gaps. Ontology suggestions emphasize established terms while avoiding unsupported precision.*